What question did this study set out to answer?

To evaluate whether adding adjuvant chemotherapy during and after pelvic radiotherapy improves overall and failure-free survival compared with radiotherapy alone in women with high-risk endometrial cancer.

February 12, 2018The Lancet OncologyOpen Access

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

View Full Paper

Ask AI

Bookmark

To evaluate whether adding adjuvant chemotherapy during and after pelvic radiotherapy improves overall and failure-free survival compared with radiotherapy alone in women with high-risk endometrial cancer.
International, open-label, multicentre, randomised phase 3 trial (PORTEC-3, NCT00411138) enrolling 660 eligible women assigned 1:1 to chemoradiotherapy (n=330) or pelvic radiotherapy alone (n=330).
Randomization used a biased-coin minimisation procedure stratified by participating centre, lymphadenectomy, cancer stage, and histological type, evaluated over a median follow-up of 60.2 months.
Five-year overall survival was 81.8% (95% CI 77.5–86.2) with chemoradiotherapy versus 76.7% (95% CI 72.1–81.6) with radiotherapy alone (adjusted HR 0.76, 95% CI 0.54–1.06; p=0.11).
Five-year failure-free survival was 75.5% (95% CI 70.3–79.9) in the chemoradiotherapy group compared with 68.6% (95% CI 63.1–73.4) in the radiotherapy group (adjusted HR 0.71, 95% CI 0.53–0.95; p=0.022).
Grade 3 or worse adverse events during treatment occurred in 60% (198/330) of chemoradiotherapy patients versus 12% (41/330) of radiotherapy patients (p<0.0001), with persistent grade 2 or worse neuropathy at 3 years remaining higher with chemoradiotherapy (8% vs 1%; p<0.0001).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial reveals improved failure-free survival without significant overall survival gains in high-risk endometrial cancer, indicating a need for individualized treatment counseling.

Cite This Study

Boer et al. (2018) studied this question.

synapsesocial.com/papers/69ff9ef84716aad0cc856a76 https://doi.org/10.1016/s1470-2045(18)30079-2

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial reveals improved failure-free survival without significant overall survival gains in high-risk endometrial cancer, indicating a need for individualized treatment counseling.

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Key Points

Discussion

Implication

Cite This Study

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider